PATENT CLAIM ANALYSIS

Application Number: 15973088
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-01
Patent Classification: ["514", "04400A"]

Abstract:
Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.

Claim (Index 18):
The method of  claim 16 , wherein the modified oligonucleotide has a nucleobase sequence comprising a region of at least 12 contiguous nucleobases which is 90% complementary to an equal length region of nucleobases 606-656 of SEQ ID NO:1, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage or at least one modified sugar.

Metadata:
- Claim Count in Document: 89.0
- Percentile: 93.0
- Lexical Diversity: 1.56757
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15127352', '15127358', '14436030', '14436024', '15028626']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8126174832829701
- 35 USC 102 Novelty (BERT): 0.5927877793281671
- Combined Prediction Score: 0.7906345128874898
- Mean Citation Score: 421.951742
- Max Citation Score: 586.1248
- Similarity Product: 442.7906413146973

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test